FDMT Total Current Liabilities from 2010 to 2025
| FDMT Stock | USD 3.63 0.07 1.97% |
Total Current Liabilities | First Reported 2018-12-31 | Previous Quarter 29.5 M | Current Value 29.1 M | Quarterly Volatility 5.6 M |
Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 28.4 M, Interest Income of 28.4 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 8.5 K, Dividend Yield of 0.0 or PTB Ratio of 0.62. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.
FDMT | Total Current Liabilities |
Latest 4D Molecular's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of 4D Molecular Therapeutics over the last few years. Total Current Liabilities is an item on 4D Molecular balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of 4D Molecular Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. 4D Molecular's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
FDMT Total Current Liabilities Regression Statistics
| Arithmetic Mean | 11,388,289 | |
| Geometric Mean | 9,712,326 | |
| Coefficient Of Variation | 61.27 | |
| Mean Deviation | 5,897,075 | |
| Median | 8,054,000 | |
| Standard Deviation | 6,977,637 | |
| Sample Variance | 48.7T | |
| Range | 23.2M | |
| R-Value | 0.85 | |
| Mean Square Error | 14.1T | |
| R-Squared | 0.73 | |
| Significance | 0.000025 | |
| Slope | 1,251,867 | |
| Total Sum of Squares | 730.3T |
FDMT Total Current Liabilities History
About 4D Molecular Financial Statements
4D Molecular shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 29.1 M | 17 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.